Interleukin-2
Title: Interleukin-2
CAS Registry Number: 85898-30-2
Additional Names: T-Cell growth factor; TCGF; thymocyte stimulating factor; costimulator; lymphocyte mitogenic factor; IL-2
Literature References: Pleiotropic cytokine produced by T-lymphocytes following activation by antigens or mitogens in the presence of IL-1, q.v. Native, human IL-2 is a glycoprotein containing 133 amino acid residues; mol wt ~15 kDa. Potent immunomodulator with important role in activating and maintaining the immune response. Induces growth and proliferation of CD4+ and CD8+ T cells; enhances natural killer cell activity; stimulates antigen secretion; potentiates the release of g-interferon and other cytokines. Also serves to down-regulate the immune system to prevent autoimmunity. Identification of soluble mitogenic factor produced by T-cells in response to antigen: R. S. Geha, E. Merler, Cell. Immunol. 10, 86 (1974). Identification of T-cell growth promoting factor produced by mitogen stimulated lymphocytes: D. A. Morgan et al., Science 193, 1007 (1976). Definition and nomenclature: L. A. Aarden et al., J. Immunol. 123, 2928 (1979). Induction of IL-2 production by IL-1: K. A. Smith et al., J. Exp. Med. 151, 1551 (1980). Review of early studies: J. Watson, D. Mochizuki, Immunol. Rev. 51, 257 (1980). Purification and partial amino acid sequence: R. J. Robb et al., Proc. Natl. Acad. Sci. USA 80, 5990 (1983). Expression of cloned cDNA for human IL-2 and predicted amino acid sequence: T. Taniguchi et al., Nature 302, 305 (1983). Isolation of human IL-2 gene: S. Mita et al., Biochem. Biophys. Res. Commun. 117, 114 (1983). Purification and cloning of the T-cell surface receptor for IL-2: W. J. Leonard et al., Nature 311, 626 (1984). Review of recombinant IL-2 muteins: L. T. Vlasveld, E. M. Rankin, Cancer Treat. Rev. 20, 275-311 (1994). Review of pharmacology and therapeutic use in cancer: R. Whittington, D. Faulds, Drugs 46, 446-514 (1993); of function, production and clinical applications: S. L. Gaffen, K. D. Liu, Cytokine 28, 109-123 (2004).
Properties: Isoelectric point: 6.5-6.8 (human); 3.9-5.0 (mouse). Sensitive to trypsin, chymotrypsin, sodium dodecyl sulfate. Stable in 2-mercaptoethanol, urea (2-4 mol/liter), neuraminidase. Stable at pH 3-10; at 56°C for 60 min. Unstable after 30 min. at 70°C.
 
Derivative Type: Aldesleukin
CAS Registry Number: 110942-02-4
CAS Name: 125-L-Serine-2-133-interleukin 2 (human reduced)
Trademarks: Proleukin (Chiron)
Literature References: Nonglycosylated interleukin-2 mutein produced by expressing the human IL-2 gene from Jurkat leukemia cells in E. coli. Production and bioactivity: S. A. Rosenberg et al., Science 223, 1412 (1984). Clinical trial in metastatic melanoma: M. B. Atkins et al., J. Clin. Oncol. 17, 2105 (1999). Review of clinical trials in HIV-infection: A. K. Pau, J. A. Tavel, Curr. Opin. Pharmacol. 2, 433-439 (2002); in renal cell carcinoma: M. Schmidinger et al., Expert Rev. Anticancer Ther. 4, 957-980 (2004).
 
Derivative Type: Teceleukin
CAS Registry Number: 136279-32-8
CAS Name: N-L-Methionylinterleukin 2 (human)
Manufacturers' Codes: BG-8301; Ro-23-6019
Trademarks: Imunace (Shionogi)
Literature References: Human interleukin-2 produced by recombinant DNA technology. Clinical evaluation of combination with interferon-a in renal cell carcinoma: H. Miyake et al., Int. J. Oncol. 10, 338 (2005).
 
Therap-Cat: Antineoplastic; immunomodulator.

Others monographs:
Chaulmoogra OilNefopamSerotoninAdenosine Diphosphate
p-DichlorobenzeneSysteminCadmium SulfideRhodium Carbonyl Chloride
TroglitazoneCarbonyl SulfideCycloheptanonep-Toluenesulfinic Acid
OctenidineDulcinFenpropimorphRanitidine
©2016 DrugLead US FDA&EMEA